Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R.

Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59. Review.

PMID:
11750879
2.

c-Met: structure, functions and potential for therapeutic inhibition.

Ma PC, Maulik G, Christensen J, Salgia R.

Cancer Metastasis Rev. 2003 Dec;22(4):309-25. Review.

PMID:
12884908
3.

Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.

Dietrich S, Uppalapati R, Seiwert TY, Ma PC.

J Environ Pathol Toxicol Oncol. 2005;24(3):149-62. Review.

PMID:
16050800
4.

Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.

Clin Cancer Res. 2002 Feb;8(2):620-7.

5.

c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Sattler M, Salgia R.

Curr Oncol Rep. 2007 Mar;9(2):102-8. Review.

PMID:
17288874
9.

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Christensen JG, Burrows J, Salgia R.

Cancer Lett. 2005 Jul 8;225(1):1-26. Epub 2004 Nov 11. Review.

PMID:
15922853
10.

Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.

Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R.

Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1488-94. Epub 2007 Feb 23.

11.

Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins.

Weimar IS, de Jong D, Muller EJ, Nakamura T, van Gorp JM, de Gast GC, Gerritsen WR.

Blood. 1997 Feb 1;89(3):990-1000.

12.

Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.

Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J.

J Natl Cancer Inst. 1999 Sep 15;91(18):1548-56. Erratum in: J Natl Cancer Inst 2000 Jan 5;92(1):78.

PMID:
10491431
13.

A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis.

Hartmann G, Naldini L, Weidner KM, Sachs M, Vigna E, Comoglio PM, Birchmeier W.

Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11574-8.

14.

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.

Cancer Res. 2003 Oct 1;63(19):6272-81.

15.

The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review).

To CT, Tsao MS.

Oncol Rep. 1998 Sep-Oct;5(5):1013-24. Review.

PMID:
9683803
16.

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.

Cancer Res. 2000 Jan 15;60(2):342-9.

17.

c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH, Radinsky R.

Clin Exp Metastasis. 2003;20(5):421-30.

PMID:
14524531
18.

A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.

Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I, Ayalon-Soffer M.

Clin Cancer Res. 2008 Jul 15;14(14):4612-21. doi: 10.1158/1078-0432.CCR-08-0108.

20.

Supplemental Content

Support Center